Nanostart-held Curiox was awarded
"Emerging Company of the Year 2010 in Asia Pacific", on 12th March,
by BioSpectrum Asia. BioSpectrum Asia is a leading B2B media platform covering
the life sciences industry in the Asia Pacific region.
Curiox and other Asia Pacific companies were assessed on the basis of their
achievements and potential for future growth to determine companies that shall
emerge as industry leaders, in the biomedical science and biotechnology sectors,
in the coming decade. BioSpectrum’s team of industry experts evaluated
all aspects of the organizations’ performance and public profile, prior
to nominating Curiox as the winner of the award in the sector biomedical sciences.
The award was given to five more companies from other sectors in life sciences
and medical technologies.
Curiox’s "Emerging Company of the Year" award comes hot on
the heels of Curiox’s LabAutomation2010 "Innovation AveNEW"
award, earlier this year; as one of the industry’s most innovative laboratory
automation technology. This magnitude of worldwide industry acceptance and excitement
for is welcomed by the young Singaporean start-up Curiox; and comes at a crucial
time as Curiox begins to expand its products to overseas markets.
“It is truly an honour to be selected with top companies in Asia who
have been around much longer than Curiox. These awards demonstrate to our customers,
partners and competitors that our DropArray™ technology is truly innovative,
and is recognized by industry experts (on a global scale) to be beneficial and
potentially disruptive to the laboratory automation industry,” comments
Curiox’s CEO Dr Namyong Kim.
Curiox's patent-pending DropArray™ technology provides a next-generation
“wall-less” microtiter platform, and complimentary washing instrument,
to provide researchers with better quality of data, 10 - 50 times savings in
sample and reagent consumption, and up to 60 % assay time reduction. Additionally,
DropArray™ technology promotes integration with liquid handling systems
by maintainaining reproducibility and compatibility with existing microtiter
plate detection systems.
Curiox Biosystems intends to penetrate the United States, European and Japanese
laboratory markets this year through strategic partnerships and distributors.
According to BioSpectrum Asia, it has a readership of over 150,000 (including
print magazine, online-edition and website) of which a large majority represent
key decision makers in the Pharma and Biotech industry.
The Nanostart Singapore Early Stage Venture Fund I holds almost 19% in Curiox
Nanostart AG is the world’s leading nanotechnology investment company.
The Frankfurt-based company provides venture capital financing for nanotechnology
companies in various growth phases. It also provides the benefits of its experience
and expertise to developers of financial instruments and to investors in the
nanotechnology sector. .
Curiox Biosystems has a vision to accelerate the progress of life sciences
and drug discovery through better miniaturization. Curiox is a bioinstrumentation
company enabling the miniaturization of heterogeneous bioassay for researchers
working in life sciences, drug discovery, and diagnostics. Curiox’s patented
miniaturization platform, DropArray™, provides up to 1,000 times savings
in sample and reagent consumption, and up to 10 times reduction in assay time.
The company is located in Singapore, the biomedical hub of Southeast Asia. The
company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN)
backed primarily by Nanostart and Exploit Technologies, the commercializing
arm of Singapore’s Agency for Science, Technology and Research (A*STAR).